Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press1610.17650/1726-9784-2015-14-2-39-46REVIEWSОБЗОРЫ ЛИТЕРАТУРЫROLE OF ESTROGEN RECEPTOR BETA IN THE DEVELOPMENT AND TREATMENT OF BREAST CANCERЭСТРОГЕНОВЫЕ РЕЦЕПТОРЫ БЕТА КАК МАРКЕРЫ ЭФФЕКТИВНОСТИ ГОРМОНАЛЬНОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫRodionovaM. V.РодионоваМария Валерьевна
Russian Federation
miss.rodionova@gmail.comVorotnikovI. K.ВоротниковИ. К.
Russian Federation
RodionovV. V.РодионовВ. В.
Russian Federation
ChkhivadzeN. V.ЧхиквадзеН. В.
Russian Federation
DudkoE. A.ДудкоЕ. А.
Russian Federation
RyabchikovD. A.РябчиковД. А.
Russian Federation
OshkinaE. V.ОшкинаЕ. В.
Russian Federation
BogushT. A.БогушТ. А.
Russian Federation
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина»Ульяновский государственный университет30062015142394610042018https://bioterapevt.abvpress.ru/jour/article/view/16

Estrogen receptors are one of the major targets in cancer cells, acting on which it is possible not only to control the processes of carcinogenesis, but also to inhibit tumor cells growth. Brilliant confirmation of this is the results of long-term application of the first targeted therapy - antiestrogen tamoxifen - in breast cancer patients with positive hormonal status of the tumor. Being discovered in the 90s, estrogen receptor beta enhanced the understanding of estrogen-mediated signaling pathway and receptor-related interactions. This review of the literature presents data on the history of the discovery, structure and functional activity of selective estrogen receptor beta, and the results of existing clinical trials which have shown the predictive role of this marker.

Рецепторы эстрогенов являются важнейшей клеточной мишенью, воздействуя на которую, можно не только контролировать процессы канцерогенеза, но и подавлять рост опухолевых клеток. Блестящим подтверждением этого стали результаты многолетнего применения первого таргетного препарата антиэстрогена тамоксифена у больных раком молочной железы с положительным рецепторным статусом опухоли. Открытие в 1990-х годах эстрогенового рецептора бета расширило понимание механизмов эстроген-опосредованного сигнального пути и межрецепторных взаимодействий. В обзоре литературы представлены данные о строении и функциональной активности эстрогеновых рецепторов бета, а также результаты клинических исследований, показавших предиктивную роль маркера при лечении рака молочной железы.

рак молочной железыэстрогеновые рецепторытамоксифенпредиктивный маркерbreast cancerestrogen receptorstamoxifenpredictive biomarkerБогуш Т.А., Дудко Е.А., Бёме A.A. и др. Экспрессия эстрогеновых рецепторов в опухолях, отличных от рака молочной железы // Антибиотики и химиотер. - 2009. - Т. 54, № 7-8. - С. 41-9.Богуш Т.А., Дудко Е.А., Бёме А.А. и др. Эстрогеновые рецепторы, антиэстрогены и немелкоклеточный рак лёгкого // Биохимия. - 2010. - Т. 75, № 12. - С. 1633-41.Богуш Т.А., Шатурова А.С., Дудко Е.А. и др. Сравнительная оценка экспрессии эстрогеновых рецепторов бета в ткани немелкоклеточного рака легкого и метастазов в легком опухолей других первичных локализаций // ДАН. - 2014. - Т. 454, № 6. - С. 720-4.Богуш Т.А., Шатурова А.С., Дудко Е.А. и др. Количественная иммунофлуоресцентная оценка с использованием проточной цитофлуориметрии экспрессии эстрогеновых рецепторов З в солидных опухолях человека // Вестн. Моск. ун-та Сер. 2, Химия. - 2011. - Т. 52, № 4. - С. 305-12.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. М.: Издательская группа РОНЦ, 2014. - С. 46.Шатурова А. С., Богуш Т.А., Дудко Е.А. и др. Экспрессия эстрогеновых рецепторов З и З1 в ткани немелкоклеточного рака легкого человека // Антибиотики и химиотер. - 2012. - Т. 57, № 5-6. - С. 11-7.Aronica S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription // Proc Natl Acad Sci USA. - 1994. - 91. - P. 8517-21.Beato M. Gene regulation by steroid hormones // Cell. - 1989. - 56. - P. 335-44.Beekman J.M., Allan G.F., Tsai S.Y. et al. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain // Mol Endocrinol. - 1993. - 7. - P. 1266-74.Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promotercontext dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen // EMBO J. - 1990. -9. - P. 2811-8.Bogush T., Dudko E., Bogush E. et al. Tamoxifen non-estrogen receptor mediated molecular targets // Oncology reviews. - 2012. - 6:e15. - P. 122-9.Bozkurt K., Kapucuoglu N. Investigation of immunohistochemical ERalpha, ERbeta and ERbetacx expressions in normal and neoplastic breast tissues // Pathol. Res. Pract. - 2012. - 208. - P. 133-9.Castoria G., Migliaccio A., Bilancio A. et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells // EMBO J. - 2001. - 20. - P. 6050-9.Collins R., Davies C. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials // Lancet. - 1998. - 351. - P. 1451-67.Cowley S.M., Parker M.G. A comparison of transcriptional activation by ER alpha and ER beta // J Steroid Biochem Mol Biol. - 1999. - 69. - P. 165-75.Davies C., Godwin J., Gray R. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials // Lancet. - 2011. - 378. - P. 771-84.Evans R.M. The steroid and thyroid hormone superfamily // Science. - 1988. - 240. - P. 889-95.Giguere V., Yang N., Segui P., Evans R.M. Identification of a new class of steroid hormone receptors // Nature. -1988. - 331. - P. 91-4.Green G.L., Gilna P., Waterfield M. et al. Sequence and expression of human estrogen receptor complementary DNA // Science. - 1986. - 231. - P. 1150-4.Green S., Walter P., Kumar V. et al. Human oestrogen receptor cDNA: sequence, expression and homology to verb-A // Nature. - 1986. - 320. - P. 134-9.Gronemryer H., Laudet V. Transcription factors 3: nuclear receptors // Protein Profile. - 1995. - 2. - P. 1167-322.Hanstein B., Liu H., Yancisin M., Brown M. Functional analysis of a novel estrogen receptor-b isoform // Mol Endocrinol. - 1999. - 13. - P. 129-37.Hartman J., Lindberg K., Morani A. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts // Cancer Res. - 2006. - 66. - P. 11207-13.Honma N., Saji S., Kurabayashi R. et al. Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast // Apmis. - 2008. - 116. - P. 923-30.Hopp T., Weiss H., Parra I. et al. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer // Clinical Cancer Research. - 2004. - 10. - P. 7490-9.Improta-Brears T., Whorton A.R., Codazzi F. et al. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium // Proc Natl Acad Sci USA. - 1999. - 96. -P. 4686-91.Jensen E.V., Jacobsen H.I. Basic guides to the mechanism of estrogen action // Rec Prog Horm Res. - 1962. - 18. -P. 387-414.Katzenellenbogen J.A., Katzenellenbogen B.S. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses // Chem Biol. - 1996. - 3. - P. 529-36.Kraus W.L. Mclnerney E.M., Katzellenbogen B.S. Ligand-dependent transcriptionally productive association of the amino- and carboxy-terminal regions of a steroid hormone nuclear receptor // Proc Natl Acad Sci USA. - 1995. -92. - P. 12314-8.Kraus W.L., Kadonaga J.T. P300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation // Genes Dev. - 1998. - 12. - P. 331-42.Kuiper G.G., Enmar E., Pelto-Huikko M. et al. Cloning of a novel receptor expressed in rat prostate and ovary // Proc Natl Acad Sci USA. - 1996. - 93. - P. 5925-30.Kuiper G.G., Lemmen J.G., Lemmen J.G. et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta // Endocrinology. - 1998. - 139. - P. 4252-63.Lagerkrantz J., Nordenskjo L.D., Gustafsson J.A. Human estrogen receptor b-gene structure, chromosomal localisation and expression pattern // J Clin Endocrinol Metab. - 1997. - 82. - P. 4258-65.Lazennec G., Bresson D., Lucas A. et al. ERβ inhibits proliferation and invasion of breast cancer cells // Endocrinology. - 2001. - 142. - P. 4120-410.Losel R., Wehling M. Nongenomic actions of steroid hormones // Nat Rev Mol Cell Biol. - 2003. - 4. - P. 46-56.Mangelsdorf D.J., Thummel C., Beato M. et al. The nuclear receptor superfamily: the second decade // Cell. - 1998. - 83. - P. 835-9.Mann S., Laucirica R., Carlson N. et al. Estrogen receptor beta expression in invasive breast cancer // Human Pathology. - 2001. - 32. - P. 113-8.Marotti J., Collins L., Hu R., Tamimi R. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study // Mod. Pathol. - 2010. - 23. - P. 197-204.Mclnerney E.M., Katzellenbogen B.S. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation // J Biol Chem. - 1996. - 271. - P. 24172-8.Migliaccio A., Di Domenico M., Castoria G. et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by es-tradiol-receptor complex in MCF-7 cells // EMBO J. - 1996. - 15. - P. 1292-300.Miller W., Anderson T., Dixon J., Saunders P. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment // Br. J. Cancer. - 2006. - 94. - P. 1333-8.Moore J.T., McKee D.D., Slentz-Kesler K. et al. Cloning and characterisation of human estrogen receptor beta isoforms // Biochem Biophys Res Comm. - 1998. - 247. - P. 75-8.Murphy L., Watson P. Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? // Endocr Relat Cancer. - 2006. - 13. - P. 327-34.Murphy L., Cherlet T., Lewis A. et al. New insights into estogen receptor function in human breast cancer // Annals of Medicine. - 2003. - 35. - P. 614-31.Myers E., Fleming F., Crotty T. et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer // Br. J. Cancer. - 2004. - 91. - P. 1687-93.Nakopoulou L., Lazaris A., Panayotopoulou E. et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer // J. Clin. Pathol. - 2004. - 57. - P. 523-8.Novelli F., Milella M., Melucci E. et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study // Breast Cancer Res. - 2008. - 10. - P. 74.O’Neill P., Davies M., Shaaban A. et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers // British Journal of Cancer. - 2004. - 91 - P. 1694-702.Osborne C. Steroid hormone receptors in breast cancer management // Breast Cancer Research Treatment. - 1998. - 51. - P. 227-38.Paruthiyil S., Parmar H., Kerekatte V. et al. Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest // Cancer Res. - 2004. - 64. - P. 432-8.Peng B., Lu B., Leygue E., Murphy L. Putative functional characteristics of human estrogen receptor-beta isoforms // Journal of Molecular Endocrinology. - 2003. - 30. - P. 13-29.Pettersson K., Delaunay F., Gustafsson J.A. Estrogen receptor β acts as a dominant regulator of estrogen signaling // Oncogene. - 2000. - 19. - P. 4970-8.Poola I., Abraham J., Baldwin K., et al. Estrogen receptors β4 and β5 are full-length functionally distinct ERß isoforms: cloning from human ovary and functional characterization // Endocrine. - 2005. - 27. - P. 227-38.Razandi M., Pedram A., Greene G.L., Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERß expressed in Chinese hamster ovary cells // Mol Endocrinol. - 1999. - 13. - P. 307-19.Saji S., Hirose M., Toi M. Clinical significance of estrogen receptor beta in breast cancer // Cancer Chemotherapy and Pharmacology. - 2005. - 56. - P. 21-6.Seol W., Choi H.S., Moore D.D. An orphan nuclear hormone receptor that lacks a DNA binding domain and het-erodimerizes with other receptors // Science. - 1996. - 272. - P. 1336-9.Shaaban A., Green A., Karthik S. et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients // Clin. Cancer Res. - 2008. - 14. - P. 5228-35.Shibata H., Spencer T.E., Onate S.A. et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action // Rec Prog Horm Res. - 1997. - 52. - P. 141-65.Sotoca A.M., van den Berg H., Vervoort J. et al. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells // Toxicol Sci. - 2008. - 105(2). - P. 303-11.Stewart J., King R., Hayward J. et al. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis // Breast Cancer Res Treat. - 1982. - 2. - P. 243-50.Sugiura H., Toyama T., Hara Y. et al. Expression of estrogen receptor beta wild-type and its variant ERbe-tacx/beta2 is correlated with better prognosis in breast cancer // Jpn. J. Clin. Oncol. - 2007 - 37. - P. 820-8.Tsai M.G., O’Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members // Annu Rev Biochem. - 1994. - 63. - P. 451-86.Vinayagam R., Sibson D., Holcombe C. et al. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer - a retrospective study // BMC Cancer. - 2007. - 7. - P. 131.Von Maillot K., Gentsch H.H., Gunselmann W. Steroid receptors and response to endocrine treatment and chemotherapy of advanced breast cancer // J Cancer Res Clin Oncol. - 1980. - 98. - P. 301-13.Warner M., Gustafsson J. The role of estrogen receptor beta (ERbeta) in malignant diseases - a new potential target for antiproliferative drugs in prevention and treatment of cancer // Biochem. Biophys. Res. Commun. - 2010. -396. - P. 63-6.Yan Y., Li X., Blanchard A. et al. Expression of both Estrogen Receptor-beta 1 (ER-ß1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER^-Negative Early Breast Cancer (EBC) // Annals of Oncology. - 2013. - P. 1-8.Zhao C., Matthews J., Tujague M., et al. Estrogen receptor ß2 negatively regulates the transactivation of estrogen receptor о in human breast cancer cells // Cancer Res. - 2007. - 67. - P. 3955-62.